These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7309322)

  • 1. "Treatment of obesity by femoxetine a selective 5 HT reuptake inhibitor'.
    Smedegaard J; Christiansen P; Skrumsager B
    Int J Obes; 1981; 5(4):377-8. PubMed ID: 7309322
    [No Abstract]   [Full Text] [Related]  

  • 2. Femoxetine in the treatment of obese patients in general practice. A randomized group comparative study with placebo.
    Bitsch M; Skrumsager BK
    Int J Obes; 1987; 11(2):183-90. PubMed ID: 3301710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Femoxetine in the prophylaxis of migraine--a randomised comparison with placebo.
    Zeeberg I; Orholm M; Nielsen JD; Honore PL; Larsen JJ
    Acta Neurol Scand; 1981 Dec; 64(6):452-9. PubMed ID: 6753446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. So-called "tension headache"--the response to a 5-HT uptake inhibitor: femoxetine.
    Sjaastad O
    Cephalalgia; 1983 Mar; 3(1):53-60. PubMed ID: 6850822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study.
    Andersson PG; Petersen EN
    Acta Neurol Scand; 1981 Oct; 64(4):280-8. PubMed ID: 7032183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Femoxetine - a new 5-HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine.
    Kangasniemi PJ; Nyrke T; Lang AH; Petersen E
    Acta Neurol Scand; 1983 Oct; 68(4):262-7. PubMed ID: 6606930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of whole blood serotonin in depressed patients treated with a new, selective serotonin-uptake inhibitor, femoxetine.
    Børup C; Petersen IM; le Fèvre Honoré P; Wetterberg L
    Psychopharmacology (Berl); 1979 Jun; 63(3):241-3. PubMed ID: 113809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic hepatitis due to femoxetine.
    Aunsholt NA; Agnholt J
    Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):253-4. PubMed ID: 3716819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled double-blind study of femoxetine and amitriptyline in patients with endogenous depression.
    Reebye PN; Yiptong C; Samsoon J; Schulsinger F; Fabricius J
    Pharmacopsychiatria; 1982 Sep; 15(5):164-9. PubMed ID: 6757983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of obesity in general practice with femoxetine. A controlled clinical trial of the effects of femoxetine and placebo].
    Kristensen JS; Christiansen P; Skrumsager BK
    Ugeskr Laeger; 1982 Mar; 144(13):939-42. PubMed ID: 7048680
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in platelet function and blood serotonin level in migraine patients during treatment with femoxetine.
    Dalsgaard-Nielsen J; le Fèvre Honoré P; Zeeberg I
    Acta Neurol Scand; 1982 Aug; 66(2):191-8. PubMed ID: 6982585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.
    Skrumsager BK; Jeppesen K
    Pharmacopsychiatry; 1986 Sep; 19(5):368-77. PubMed ID: 3774871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical profile of paroxetine: a novel selective serotonin reuptake inhibitor (SSRI).
    J Clin Psychiatry; 1992 Feb; 53 Suppl():1-68. PubMed ID: 1531815
    [No Abstract]   [Full Text] [Related]  

  • 14. Depression and selective serotonin reuptake inhibitors.
    Westwick F
    Br J Hosp Med; 1990 Nov; 44(5):367. PubMed ID: 2148896
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel selective serotonin reuptake inhibitors, Part II.
    J Clin Psychiatry; 1992 Jun; 53(6):216-21. PubMed ID: 1535073
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting 5-HT receptors for the treatment of obesity.
    Sargent BJ; Henderson AJ
    Curr Opin Pharmacol; 2011 Feb; 11(1):52-8. PubMed ID: 21330209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical overview of serotonin reuptake inhibitors.
    Rickels K; Schweizer E
    J Clin Psychiatry; 1990 Dec; 51 Suppl B():9-12. PubMed ID: 2147922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study.
    Suominen J; Tamminen T; Elosuo R; Manniche PM
    Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An early clinical phase II evaluation of paroxetine, a new potent and selective 5HT-uptake inhibitor in patients with depressive illness.
    Børup C; Meidahl B; Petersen IM; Vangtorp A; le Fèvre Honoré P
    Pharmacopsychiatria; 1982 Nov; 15(6):183-6. PubMed ID: 6218507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
    Tulloch IF; Johnson AM
    J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.